← 89bio, Inc. (ETNB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
89bio, Inc. (ETNB)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
89bio, Inc. (ETNB) is a clinical-stage pharmaceutical company with a market cap of approximately $2.2B and 93 employees, focused primarily on liver and cardiometabolic diseases. Its lead asset, pegozafermin, is in Phase 3 development for MASH/NASH with compensated cirrhosis — one of the most competitive and high-stakes indications in biopharma. A second asset, BIO89-100, is in Phase 2 for NASH, but limited public data on both pipeline assets and financials constrain the full picture.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BIO89-100 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| Pegozafermin | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis |
Price & technical context
3-month
+62.0%
6-month
+82.5%
12-month
+85.0%
52-wk range
$4.83–$14.96
vs 50-day MA
+18.5%
vs 200-day MA
+51.5%
Realized vol
98.4%
Max drawdown
-69.9%
Daily closes through 2025-10-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ETNB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.